Spero Therapeutics (SPRO) Depreciation & Amortization (CF) (2016 - 2024)

Spero Therapeutics (SPRO) has 9 years of Depreciation & Amortization (CF) data on file, last reported at $2000.0 in Q2 2024.

• Quarterly Depreciation & Amortization (CF) fell 98.15% year-over-year to $2000.0 in Q2 2024, while the trailing twelve-month figure through Mar 2025 was $2000.0 (down 99.21% YoY) and the FY2024 annual result came in at $2000.0, down 99.46% from the prior year.
• Depreciation & Amortization (CF) fell to $2000.0 in Q2 2024, from $38000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $294000.0 in Q2 2022 to a low of $2000.0 in Q2 2024.
• A 5-year average of $157882.4 and a median of $159000.0 in 2021 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2020 — Depreciation & Amortization (CF) surged 307.21% — and 2024, when it sank 98.15%.
• Tracing SPRO's Depreciation & Amortization (CF) over 5 years: stood at $230000.0 in 2020, then dropped by 16.96% to $191000.0 in 2021, then slumped by 32.46% to $129000.0 in 2022, then tumbled by 70.54% to $38000.0 in 2023, then tumbled by 94.74% to $2000.0 in 2024.
• The last three Depreciation & Amortization (CF) figures came in at $2000.0 (Q2 2024), $38000.0 (Q4 2023), and $108000.0 (Q3 2023), per Business Quant data.